Estimation of renal cell carcinoma treatment effects from disease progression modeling

To improve future drug development efficiency in renal cell carcinoma (RCC), a disease progression model was developed with longitudinal tumor size data from a phase III trial of sorafenib in RCC. The best fit model was externally evaluated on 145 placebo-treated patients in a phase III trial of paz...

Descripción completa

Detalles Bibliográficos
Autores principales: Maitland, Michael L., Wu, Kehua, Sharma, Manish R., Jin, Yuyan, Kang, Soonmo Peter, Stadler, Walter M., Karrison, Theodore G., Ratain, Mark J., Bies, Robert R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791430/
https://www.ncbi.nlm.nih.gov/pubmed/23443753
http://dx.doi.org/10.1038/clpt.2012.263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791430/
https://www.ncbi.nlm.nih.gov/pubmed/23443753
http://dx.doi.org/10.1038/clpt.2012.263

Ejemplares similares